摩根士丹利大幅上調康希諾目標價,因新冠疫苗成功機率上升
彭博新聞社報導 ,摩根士丹利表示,康希諾生物成功研發出新冠疫苗的機率上升,此前《柳葉刀》稱初步資料顯示其療法安全性良好。
摩根士丹利分析師Yolanda Hu等人在報告中表示,目前估計疫苗的成功率在60%,此前為20% 。
預計其疫苗將在今年年底或明年年初獲批。
將其目標價從102港元上調至258港元,維持增持評級。
康希諾生物-B週一在香港一度升逾8%,但開盤不久就快速下挫,截至北京時間10時,康希諾生物-B跌11.71%,報196港元,振幅高達19%。

圖片來源:uSMART友信智投
康希諾生物-B近期股價波動劇烈,投資者需要注意風險。疫苗的有效性,最終看三期臨床實驗,正如市場人士分析指出,投資者沒有人知道康希諾生物到底值多少,人們在押注其疫苗的成功,但目前試驗僅在第二階段,並且有可能失敗。
免責聲明:本文所載的所有資料、資料等(「資料」)只供參考之用,不構銷售或建議任何投資、交易策略或金融產品的要約或招攬。本公司會盡力確保資料的準確性及可靠性, 但不保證該資料為準確無誤, 亦不承擔因任何不準確或遺漏而引起的損失或損害。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.